Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of repeated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: A medical endodevice for an intervention inside a human or animal body includes an elongated liaising structure having a distal end arrangeable inside a body of the human or animal being and a proximal end arrangeable outside the body while the distal end is inside the body. The endodevice has an intervention tool arranged to manipulate a target tissue inside the human or animal body. The intervention tool is arranged at the distal end of the liaising structure. The endodevice further includes a positioning unit having a moving formation arranged to dislocate the intervention tool relative to the target tissue, and an anchoring formation arranged to fix the moving formation to a fixing tissue inside the human or animal body such that the target tissue is positioned in a workspace of the intervention tool.

Abstract: The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.

Abstract: The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.

Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

Abstract: Device and method for comminution or inactivation of circulating tumor cells (CTC) or tumor cell clusters (CTCC) from a tumor-affected organ or organ part, wherein it is proposed that in the venous drain of the tumor-affected organ or organ part a pump (2) with a pressure-increasing section and a pressure-reducing throttle (13) is arranged and is operated at the output side in its design point given by volumetric flow (Q) and pumping pressure (p) according to the volumetric flow and the blood pressure of the venous drain of the tumor-affected organ or organ part. Circulating tumor cells (CTC) and tumor cell clusters (CTCC) are thus comminuted and inactivated to thus reduce the risk of metastasis formation in cancerous diseases.

Abstract: For exploiting novel use-cases, in particular sophisticated human-machine interaction, with an intraoral electronic tongue monitoring system designed to be worn by a user on the upper or lower jaw and featuring a support sheet bearing a number of intraoral sensors arranged in an array for recording tongue movement and/or tongue pressure, it is proposed that the system comprises at least one extraoral sensor located outside of the oral cavity delimited by the teeth when the system is in place, in particular such that extraoral and/or intraoral and/or interlabial movements of the tongue and/or lip pressure can be recorded with the system and/or such that the system may be used as an input device controlled through tongue movement using a human-machine-interface provided by the system.

Abstract: The present application relates to Pichinde viruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular. described herein is a modified Pichinde virus genomic segment, wherein the Pichinde virus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented Pichinde virus particles comprising one L segment and two S segments or two L segments and one S segment. The Pichinde virus, described herein may be suitable for vaccines md/or treatment of diseases and/or for the use in immunotherapies.

Abstract: Quantitative susceptibility mapping methods, systems and computer-accessible medium include generating images of tissue magnetism property from complex magnetic resonance imaging data using the Bayesian inference approach. The tissue magnetism images is then used to monitor remyelination, such as remyelination in multiple sclerosis patients in response to therapy. Multiple sclerosis lesions defined on magnetic resonance imaging are further characterized on tissue magnetism images into hyperintense, isointense and hypointense parts for measuring remyelination. Thus, magnetic susceptibility information and other tissue properties associated with at least one structure are determined.

Abstract: The present invention relates to the use of a combination of plant extracts from the genera Salvia, Artemisia, Echinacea, and optionally further plant extracts, for the cosmetic treatment of the skin. The invention further relates to cosmetic preparations which comprise such combination of plant extracts. These plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system, including rejuvenation, anti-ageing, detoxification and increased firmness of the skin, for puffy-eye treatment and/or for anti-swelling effects.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, comprising the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each comprising an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, —Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: The invention relates to an apparatus (100) for determining properties of a sample (110) arranged in at least one receptacle (130) of a container device (120). The apparatus (100) comprises an actuator (30) which is configured to be coupled to the sample (110) via at least one holding element (34) which is configured to hold the sample (110). Further, the actuator (30) is configured to apply a mechanical stimulus to the sample (110) via the at least one holding element (34). The apparatus (100) comprises a force sensing device (20) which is configured to be coupled to the sample (110) via at least one cantilever (22). Further, the apparatus (100) comprises a frame (1), wherein the actuator (30) and the force sensing device (20) are configured to be mounted to the frame (1), and wherein the frame (1) is configured to be arranged on the container device (120).

Abstract: The invention relates to an Na+/K+ ATPase inhibitor for use in the prevention or treatment of metastasis in a cancer patient defined by the presence of CTC clusters in the bloodstream. In certain embodiments the Na+/K+ ATPase is a cardiac glycoside and is selected from: digitoxin, ouabain, convallatoxin, proscillaridin, lanatoside C, gitoformate, peruvoside, strophanthidin, metildigoxin, deslanoside, bufalin, digoxin and digoxigenin. The invention further relates to the use of nucleic acid agents inhibiting the expression of genes related to CTC cluster formation and maintenance.

Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.

Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.

Abstract: The present invention relates to compounds of formula (A), wherein Z is NR10 or O. These compounds represent novel acridinium and xanthylium salts having an unprecedented substituted heterocyclic core. They are useful as fluorescent dyes or precursors thereof in different applications including various imaging and sensing techniques, and, in particular, as photosensitizers and hereby preferably as photocatalysts. The present invention further relates to processes for preparing the inventive compounds via 1,5-organodimetallic reagents from double directed ortho-metalation reactions or combined halogen-metal exchange/directed ortho-metalation reactions.